36th Annual Congress on Vaccine and Clinical Trials is scheduled to be held during December 05-06, 2024 Vancouver, Canada. This Vaccines Congeress-2024 includes a wide range of Keynote presentations, Oral talks, Poster presentations, Symposia, Workshops, Exhibitions and Career development programs.

Conference series LLC Ltd Organizes 3000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals  which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference website will provide you list and details about the conferences organize worldwide.

Why to Attend???

Vaccines Congress-2024 Conference is a multidisciplinary program with broad participation with members from around the globe focused on learning about Vaccines and its advances. This is your best opportunity to reach the largest assemblage of participants from Vaccines community, Clinical research that is from academia, medical groups, related associations, societies and also from government agencies, biomedical and medical device industries.

Vaccines Congress-2024 will discuss various disciplines involved in the vaccines research; it will educate health care researchers about design, operation, organizing, and research computing, regulatory aspects. It promotes better understanding by the general public about the importance of vaccines in prevention, diagnosis and treatment of disease. This conference conduct presentations, distribute information, meet with current and potential scientists, make a splash with new research developments, and receive name recognition at this 2-days event. World renowned speakers and the most recent techniques, developments, the newest updates in Vaccines Research are hallmarks of this conference.

Who Should Attend?

• Principal Investigators
• Medical Directors
• Methodologists
• Directors/Executive Directors
• Vice Presidents/Senior Vice Presidents/Executive Vice Presidents
• Heads/Leaders
• Deans/Senior Professors/Associate Professor/Assistant Professors
• Research Scholars
• Scientists
• Vaccinologists
• Business Entrepreneurs
• Students
• Medical Devices Manufacturing Companies
• Vaccine Manufacturing Companies
• Vaccine Developers and Investigators

2024 Highlights:

300+ Participation (70 Industry: 30 Academia)

5+ Keynote Speakers

50+ Plenary Speakers

14 Innovative Educational Sessions

5+ Workshops

B2B Meetings

Advantages of Participating at our Conference

• The advantages of the Speaker and abstract pages are created in Google on your profile under your name would get worldwide visibility.
• Our comprehensive online advertising attracts 30000+ users and 50000+ views to our Library of Abstracts, which takes researchers and speakers to our conference.
• Meet with hundreds of like-minded experts who are pioneers in Vaccines and share ideas.
• All participants in the conference would have a different reason to participate with eminent speakers and renowned keynote speakers in one-to-one meetings.
• A rare opportunity to listen what the world's experts are learning about from the world's most influential researchers in the area of  Vaccines and Clinical Trails at our Keynote sessions.
• Vaccines intensive conference schedule, you will acquire experience and expertise in strategic gift preparation that is worth its weight golf, forming an impressive array of recognized professionals.
• Best Poster Award nominations.
• Award for Outstanding Young Researcher.
• Group Registration Advantages.

Benefits of Participation for Speaker

• Worldwide appreciation of the profile of Researchers.
• Obtain credits for professional growth.
• Explore the latest of cutting edge analysis.
• Make long-term bonds at social and networking activities.
• An ability to advertise one page in the distribution of abstract books and flyers that ultimately gets 1 million views and adds great value to your research profile.
• Learn a transition beyond your area of interest to learn more about new subjects and studies away from your  core subject of Vaccines and Clinical Trials.
• We have distinctive networking, learning and enjoyable integration into a single package.
• Each speaker has the separate Speaker profile.

Benefits of Participation for Delegate

• Professional Development-Improve understanding and knowledge.
• Attendance at  conference supports, rejuvenates and energises delegates.
• Your involvement in our conference will help with a new methodology and ideology that can be used to broaden the outcomes of businesses or industries.
• Opportunities for Vaccines researchers and experts in the same field to meet and exchange new ideas through an conference.

Benefit of Participation for Sponsor

• Exposure to the international environment would increase the possibility of new companies.
• Opportunity to demonstrate your company's latest technologies, new products, or service your business to a wide range of  international participants.
• Increase business by our conference participants through lead generation.
• It takes a lot of time, effort and drive to create a successful company, so it's always nice to have a network of colleagues and associates to draw energy from individuals who share a common drive and  objective.
• Conferences in vaccines provide opportunities for more attention and contemplation that could help you move your company to the next stage.
• Benchmarking main organization plans and moving it forward.
• Get feedback from trustworthy people at our conference to your company questions and challenges.
• On our conference banner, website and other proceedings, branding and marketing content, the advertising logo of your company.

Benefit of Association for Collaborators

• Nobody has this massive visitors to Vaccines and Clinical Trials in the world, this is the best forum to highlight society.
• Creating long-lasting peer relationships.
• In our conference banner, website and other proceedings, branding and marketing material, promotional content and your Organization logo will increase your number of subscribers/members by 40%.
• The exposure of our event to your Company listing in the Global Business forum will have a great effect on your association.
• Your representatives can network to update their knowledge and understanding of your organisation and services with key conference delegates.
• Vaccines advertising materials such as posters, brochures, pamphlets, services that will be circulated to hospitals, universities, society and researchers will be integrated with information.

A vaccine activates our immune system while not making us sick. Various dangerous infectious diseases are often prevented in this simple and effective way. Vaccination could be a simple, safe, and effective way of protecting individuals against harmful diseases, before they are available into contact with them. It uses your body’s natural defenses to make resistance to specific infections and makes your immune system stronger. Vaccines train your immune system to form antibodies, just as it does when it’s exposed to a disease. However, as a result of vaccines contain only killed or weakened varieties of germs like viruses or bacteria, they do not cause the disease or put you at risk of its complications.

COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally Bacterial co-infections are correlated with unfavorable outcomes in respiratory viral infections. Despite, microbiological and antibiotic data related to COVID-19 are skimpy, competent use of antibiotics in line with antibiotic stewardship (ABS) principles is guaranteed during the pandemic. Bacterial and fungal co-infections are subtle in COVID-19 patients and are mainly ubiquitous in critically ill patients. In addition, studies are needed to estimate the impact of antimicrobial therapy on therapeutic outcomes in COVID-19 patients to prevent antimicrobial overuse. A novel beta-coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was consequently identified as the causative pathogen. Ordinarily, respiratory viral infections are a risk factor for bacterial co-infections, which then increase disease austerity and mortality. It has been established that sepsis and ventilator-associated pneumonia are frequently observed complications in COVID-19 patients.

Cancer vaccines are a form of immunotherapy that can help educate the immune system about what cancer cells “look like” so that it can recognize and eliminate them.

Vaccines have proven effective in preventing diseases caused by viruses and bacteria. Since the first vaccine was developed more than 200 years ago, they have prevented some of the twentieth century’s deadliest diseases and have helped save hundreds of millions of lives globally.

In the case of diseases caused by viruses (e.g., measles, polio, and smallpox) and bacteria (e.g., diphtheria, tetanus, and tuberculosis), vaccines work by exposing people to a weakened or inactivated version of the threat. This enables their immune system to identify these threats according to their specific markers—known as “antigens”—and mount a response against them. These vaccines typically work best in the preventive setting, when an individual is given the vaccine before being infected by the bacteria or virus.

In the case of cancer, however, the situation is more complicated for several reasons (more below) and this has made it more difficult to develop vaccines to either prevent or treat cancer. In particular, unlike bacteria and viruses, which appear foreign to our immune system, cancer cells more closely resemble our normal, healthy cells. Furthermore, each individual’s tumor is in some sense unique and has its own distinguishing antigens. As a result, more sophisticated approaches are necessary to develop effective cancer vaccines.

• Preventive Cancer Vaccines
• Therapeutic Cancer Vaccines
• Personalized Neoantigen Vaccines

Preventive Cancer Vaccines:

Viral infections are responsible for the development of several cancers and preventive vaccines play an important role in reducing risk. For instance, cervical cancer and head and neck cancer can be caused by human papilloma virus, or HPV, whereas liver cancer can be caused by hepatitis B virus or HBV. Several vaccines have been developed that can prevent HBV and HPV infection and, as a result, protect against the formation of HBV- and HPV-related cancers.

Four of these preventive cancer vaccines have been approved by the U.S. Food and Drug Administration (FDA).

Therapeutic Cancer Vaccines:

Each individual’s tumor is in some sense unique and has its own distinguishing antigens. As a result, more sophisticated cancer vaccine approaches are necessary. Fortunately, doctors can now identify targets on patients’ tumors that can help distinguish cancer cells from their normal cells. Sometimes these targets are normal proteins that are produced at abnormally high levels by cancer cells, such as prostatic acid phosphatase (PAP), which is often overexpressed by prostate cancer cells. Taking advantage of that insight, the sipuleucel-T vaccine was developed and received FDA approval in 2010 for the treatment of patients with advanced prostate cancer. Additionally, virus-derived proteins expressed by virus-infected cancer cells offer another promising source of markers that can be targeted through vaccines. Another exception is Bacillus Calmette-Guérin, or BCG, a tuberculosis vaccine that acts as a general immune stimulant. In 1990, BCG became the first immunotherapy of any type to be approved by the FDA and is still used for the treatment of early-stage bladder cancer.

Toxoid vaccinations are created utilizing a toxic substance (hurt) that has been made safe anyway that moves a safe response against the toxic substance. Rely upon the toxic substance made by explicit organisms (for example tetanus or diphtheria). The toxic substance assaults the circulatory framework and is, as it were, accountable for the reactions of the disease. The protein-based toxic substance is rendered harmless and used as the antigen in the inoculation to summon insusceptibility.

Researchers adopt numerous strategies to structuring antibodies against an organism. These decisions are commonly founded on crucial data about the microorganism, for example, how it taints cells and how the resistant framework reacts to it, just as useful contemplations, for example, districts of the existence where the antibody would be utilized. A DNA and RNA immunization against a microorganism would bring out a solid neutralizer reaction to the free-gliding antigen emitted by cells, and the antibody likewise would invigorate a solid cell reaction against the microbial antigens showed on cell surfaces. The DNA and RNA antibody couldn't cause the malady since it wouldn't contain the organism, just duplicates of a couple of its qualities. Moreover, DNA antibodies are moderately simple and cheap to plan and create. Inactivated immunizations can be made out of either entire infections or microorganisms, or portions of either. Fragmentary antibodies are either protein-based or polysaccharide-based.

Vaccination during pregnancy can possibly secure the mother and the new-born child against antibody preventable infections. New conceived new-born children are at high-chance for huge ailment and demise from certain irresistible maladies in light of the fact that their insusceptible framework has not completely created. One point of immunizing pregnant ladies is to expand the measure of maternal counter acting agent (proteins that battle malady) moved to babies, possibly shielding them from irresistible infection.

The Live-Attenuated antibody is created to the illness brought about by Zika Virus. The monovalent form of the antibody is planned against Zika infection contamination. Zika Virus has a place with the Genus Flavivirus, which is transmitted by the Aedes mosquitos. The comprehension of flavivirus molecule structure, meaning of E dimers as the key antigenic objective, and profound comprehension of balance instruments help to build up the immunization.

It is intriguing to view exercises of medication designers in zone of immune response prompting immunizations coordinated against non-irresistible sicknesses and some unusual signs. These immunizations have been by and large grown so far as treatment antibodies. This is in inverse to irresistible maladies antibodies utilized as prophylactic immunizations. In spite of promising late stage up-and-comers, with some extremely ongoing disappointments, there is still no immune response prompting antibody affirmed focusing on other than microorganism antigens (I. e focusing on self-antigens , enslavement particles antigens and others. It is intriguing to view exercises of medication engineers in territory of immune response actuating antibodies coordinated against non-irresistible infections and some capricious ailments.

Immunization advancement is an action that spotlights on an assortment of mechanical activities and applied research, which upgrade and advance improved frameworks and practices for antibody wellbeing. In the previous year, the uncommon Ebola malady episode aroused research and industry reaction and as we keep on looking for arrangements, we should survey the exercises learned so as to conquer the ebb and flow difficulties. Antibody improvement is a long, complex procedure, frequently enduring 10-15 years and including a mix of open and private inclusion. The present framework for creating, testing, and directing immunizations created during the twentieth century as the gatherings included institutionalized their strategies and guidelines.

Irresistible infections are answerable for around 25% of worldwide mortality, particularly in youngsters matured more youthful than 5 years. A significant part of the weight of irresistible maladies could be lightened if suitable instruments could be set up to guarantee access for all youngsters to fundamental antibodies, paying little heed to topographical area or financial status. Furthermore, new sheltered and powerful immunizations ought to be produced for an assortment of diseases against which no compelling preventive intercession measure is either accessible or handy. The general population, private, and humanitarian divisions need to unite to guarantee that these new or improved antibodies are completely created and gotten open to the populaces deprived as fast as could be allowed.

Progressively, more sicknesses are getting antibody preventable, yet keeping up network and supplier acknowledgment requests that the quantity of infusions doesn't increment. Blend conjugate antibodies speak to an inescapable and significant development. This paper surveys the adequacy and security of mix conjugate antibodies, including immunological instruments hidden cooperation’s among immunization epitopes, the job of immunological memory, and relates of invulnerability. Explicit consideration is given to the involvement in blend antibodies against each of Haemophilus influenza type b, Streptococcus pneumonia and Neisseria meningitidis. The ramifications of these discoveries for various networks are examined, key zones for further research recognized and suggestions for post-licensure checking tended to.

Antibody adequacy alludes to the capacity of immunizations to achieve the proposed useful consequences for inoculated people in a characterized populace under perfect states of utilization. The potential advantages of a successful immunization – for example advancement of wellbeing and prosperity, and assurance from ailment and its physical, mental and financial outcomes must be weighed against the potential danger of an antagonistic occasion following vaccination (AEFI) with that immunization. Antibody related hazard is the likelihood of an unfavourable or undesirable result happening, and the seriousness of the subsequent mischief to the wellbeing of inoculated people in a characterized populace following vaccination with an immunization under perfect states of utilization.

An AIDS antibody doesn't yet exist, however endeavours to build up an immunization against HIV, the infection that causes AIDS, have been in progress for a long time. A HIV antibody could be viable in both of two different ways. A "preventive" immunization would stop HIV contamination happening through and through, while a "remedial" antibody would not stop disease, however would counteract or postpone ailment in individuals who do get tainted, and may likewise lessen the danger of them transmitting the infection to others. Albeit a preventive antibody would be perfect, helpful immunizations would likewise be exceptionally gainful. The fundamental thought behind all HIV immunizations is to empower the human invulnerable framework to battle HIV. Malaria keeps on guaranteeing an expected 2 to 3 million lives every year and to represent untold dismalness in the around 300 to 500 million individuals contaminated yearly. Jungle fever is viewed as a reappearing malady, due to a great extent to the spread of medication safe parasite strains, rot of medicinal services framework and challenges in executing and keeping up vector control programs in many creating nations. Four types of protozoan parasites cause jungle fever in people: Plasmodium falciparum, P. vivax, P. malaria, and P. ovale. P. falciparum is liable for most of passings and the vast majority of the extreme types of sickness, including cerebral jungle fever. 2 billion individuals inactively tainted with M. tuberculosis 5-10% tainted individuals progress to sickness 9 million new TB cases every year 1.5 million TB passings every year Equivalent to 20 traveller flying machine crashes every day. TB is transmitted by grown-ups with citatory sickness HIV tainted individuals worry about more prominent concern of ailment. Most elevated danger of movement from TB contamination to dynamic infection, and most exceedingly terrible TB horribleness and mortality, contrasted with more established youngsters and grown-ups.

The mechanical anti-infection yield has been upgraded by innovative advancements and the advancement of strain improvement of microorganisms through arbitrary transformation and screening. The recombinant DNA innovation and its application in anti-microbial creation by microorganisms have given yield improvement and structure of biosynthetic pathways for new anti-microbial generation. Hereditary control of biosynthetic pathways is helpful procedure for creating opposing results of complex bioactive metabolites.

Anti-infection agents are screened for reactions before getting the endorsement for clinical use. A few anti-toxins have gentle to serious symptoms relying upon the kind of anti-microbial utilized, directed organisms and the individual patient. Immunizations have typically less destructive reactions like gentle fever, migraine, muscle joint agony; shuddering and so on yet hardly any antibodies have uncommon symptoms like hypersensitivity known as anaphylactic response.

Immunization is the most significant way to deal with balance irresistible infections. Therefore, the advancement of as good as ever antibodies for existing, developing, and reappearing maladies is a territory of incredible enthusiasm to established researchers and the overall population. The ongoing progressions in antibodies guard the people from the wide scope of ailments. The most capacity of the immunizations is to actuate the body substance protein reactions and cell-interceded reactions against the enormous determination of pathogens. For sure, the creation is acquainted with turning out the antibodies, immunogens and significant helpful and symptomatic reagents. Among the apparatuses accessible for illness counteractive action and control, antibodies rank high as for viability and financial plausibility. Immunization produce is one of the most testing ventures. Assembling an enemy of infection immunization today is a convoluted procedure considerably after the hard assignment of making a potential antibody in the lab.

Vaccination is progressively significant in our life for keeping us healthy. Recent years have seen the two victories and disappointments of novel antibody structure and the quality of iterative methodologies is progressively appreciated. Vaccine improvement stays testing on account of the profoundly modern avoidance instruments of pathogens for which antibodies are not yet available. These consolidate the revelation of novel antigens, adjuvants, and vectors in the preclinical stage with computational investigations of clinical information to quicken antibody plan. Every epic immunization competitor should be assessed for security, immunogenicity, and defensive adequacy in people before it is authorized.

Immunization improvement stays testing as a result of the exceptionally modern avoidance systems of pathogens for which antibodies are not yet accessible. Late years have seen the two victories and disappointments of novel antibody plan and the quality of iterative methodologies is progressively valued. These consolidate the revelation of novel antigens, adjuvants, and vectors in the preclinical stage with computational investigations of clinical information to quicken antibody plan. Switch and basic vaccinology have uncovered novel antigen up-and-comers and sub-atomic immunology has prompted the definition of promising adjuvants. Quality articulation profiles and safe parameters in patients, immunizations, and sound controls have framed the reason for bio-marks that will give rules to future antibody structure.

Introduction

The global vaccines market has witnessed remarkable growth over the past few decades, driven by advancements in medical research, increasing awareness about preventive healthcare, and the ongoing pursuit of controlling and eradicating infectious diseases. Clinical trials play a pivotal role in the development, evaluation, and approval of vaccines, ensuring their safety, efficacy, and suitability for widespread use. This market analysis delves into the key trends, drivers, challenges, and opportunities in the vaccines and clinical trials landscape.

Market Trends

1. Rising Demand for Preventive Healthcare: The increasing emphasis on preventive healthcare has elevated the demand for vaccines. Governments, organizations, and individuals recognize the significance of vaccination in curbing the spread of infectious diseases and reducing the burden on healthcare systems.

2. Technological Advancements: Innovations in biotechnology, genomics, and immunology have accelerated vaccine development. This has led to the creation of novel vaccine platforms, such as mRNA vaccines, that have shown immense potential in addressing diseases like COVID-19.

3. Global Health Initiatives: International efforts to eliminate diseases like polio, measles, and malaria have spurred investment in vaccine research and clinical trials. Public-private partnerships and collaborations are driving research forward, aiming to tackle diseases that disproportionately affect developing nations.

4. Personalized Vaccines: The concept of personalized medicine is making its way into the vaccine landscape. Tailoring vaccines to individual genetic profiles could enhance efficacy and reduce adverse effects, making clinical trials even more crucial in understanding these personalized responses.

Market Drivers

1. Pandemic Preparedness: The COVID-19 pandemic underscored the urgency of vaccine development and the vital role of clinical trials. Governments and organizations worldwide are now investing more in vaccine research to be better prepared for future health crises.

2. Growing Disease Burden: The prevalence of infectious diseases like HIV, tuberculosis, and emerging pathogens necessitates continuous vaccine research. Clinical trials are essential to evaluate new vaccines and their potential impact on disease transmission.

3. Changing Epidemiology: Shifting demographics, urbanization, and global travel patterns impact disease transmission dynamics. As diseases cross borders more easily, effective vaccines become imperative, making clinical trials essential to address changing epidemiological trends.

Challenges

1. Regulatory Hurdles: The regulatory process for vaccine approval can be lengthy and complex due to safety concerns. Balancing the need for rigorous testing with the urgency of addressing public health threats presents challenges.

2. Resource Constraints: Conducting clinical trials requires significant financial resources and skilled personnel. In resource-limited settings, this can hinder the timely development and evaluation of vaccines.

3. Vaccine Hesitancy: Misinformation and vaccine hesitancy pose obstacles to vaccine adoption. Ensuring public trust in vaccines necessitates transparent communication and evidence from robust clinical trials.

Opportunities

1. Innovative Trial Designs: Adaptive trial designs and real-world evidence integration can accelerate the vaccine development process while maintaining safety and efficacy evaluations.

2. Collaborative Research: Partnerships between academia, industry, and governments can leverage diverse expertise and resources, expediting vaccine research and development.

3. Emerging Markets: Developing countries present untapped opportunities for vaccine market growth. Tailored vaccine solutions and affordable clinical trial strategies can address specific regional health challenges.

Conclusion

The vaccines and clinical trials market is witnessing a dynamic evolution driven by scientific innovation, global health priorities, and a renewed understanding of the critical role vaccines play in disease prevention. While challenges exist, the opportunities for accelerated vaccine development, personalized medicine, and global health impact through collaborative efforts are substantial. As technology continues to shape the landscape, the role of clinical trials in ensuring safe, effective, and globally accessible vaccines remains paramount.

Data Snapshot

• The global vaccine market was valued at $58.4 billion in 2020 and is projected to reach $108.5 billion by 2027, with a CAGR of 9.3% from 2021 to 2027^1.
• In 2020, clinical trials for COVID-19 vaccines saw unprecedented speed, with multiple vaccines reaching phase III trials within months^2.
• Vaccine hesitancy resulted in a decline in measles vaccination rates, contributing to a 30% increase in reported measles cases globally between 2016 and 2019³.
• Developing countries accounted for 64% of vaccine doses administered globally in 2019, reflecting the importance of global health initiatives⁴.

Footnotes

1. Grand View Research, "Vaccine Market Size, Share & Trends Analysis Report," 2021. â†©

2. World Health Organization, "DRAFT landscape and tracker of COVID-19 candidate vaccines," 2020. â†©

3. World Health Organization, "Measles cases spike globally due to gaps in vaccination coverage," 2019. â†©

4. UNICEF, "Immunization coverage," 2020. â†©

Planning a Trip to Vancouver, Canada!!! Attending Meeting!!!

 

An issue with VISA!!

 

Vaccines Congress Committee will be happy to help you in all regards to plan your trip to Vancouver, Canada. Avail the official invitation letter from us to attend this event ahead with a closer step for approval of your VISA.

 

Find out what you need to do to visit Canada as a tourist or business person, how to extend your stay in Canada and what documents you need to carry with you to transit through Canada.

 

Application submission:

 

Canada does not have a visa office in every country so it is important that Delegates/Attendees visit the website of the visa office responsible for processing their visa applications.  Information is available on the website on how to submit a visa application and the documentation required. 

 

Delegates/Attendees are encouraged to submit their visa applications well in advance of the date of the event at a Visa Application Centre or on-line E-applications (e-Apps).

 

E-Apps

 

This system allows clients to submit applications online.

 

Delegates/Attendees that need a visa but require their passport for other travel purposes are strongly encouraged to submit their visa applications online (e-Apps).  Delegates/Attendees that choose to apply online will not have to submit their passport until a decision has been taken on their applications.  If required, the visa office will send the applicant instructions on how and where to send their passports to finalize the visa process.  

 

Visa Application Centres (VACs):

 

VACs are commercial service providers authorized by Canada to provide specific services to applicants. 

 

VACs provide a number of services including help applicants fill out forms, answer questions and ensure that applications are complete, thereby reducing unnecessary delays or refusals due to incomplete applications.

 

Applicants that are required to provide biometrics information as part of the visa application process can do so at a VAC.  Additional information on the biometrics requirements is available at the IRCC website.

 

VACs send applications to Visa Offices and transmit decisions to applicants in a secure and confidential manner. VACs do not process visa applications and play no role in the decision-making process.

 

Visa Applications Processing Time:

 

Processing time for visa applications vary depending on the office and the time of the year.  Participants should be encouraged to apply early for their visas, and to submit complete applications including all supporting documents.  

 

Please visit the IRCC website for information on the time it takes to process visa applications at the various visa offices. 

 

NEW - Electronic Travel Authorization (eTA)

 

As of March 15, 2016, visa-exempt foreign nationals are expected to have an Electronic Travel Authorization (eTA) to fly to or transit through Canada. Exceptions include U.S. citizens and travelers with a valid Canadian visa. Canadian citizens, including dual citizens, and Canadian permanent residents are not eligible to apply for an eTA.

 

However, from March 15, 2016, until fall 2016, travellers who do not have an eTA can board their flight, as long as they have appropriate travel documents, such as a valid passport. During this time, border services officers can let travellers arriving without an eTA into the country, as long as they meet the other requirements to enter Canada. We invite you to consult the IRCC website regularly for information updates on eTA.